nct_id
stringlengths 11
11
| nlm_download_date_description
float64 | study_first_submitted_date
stringlengths 10
10
| results_first_submitted_date
stringlengths 10
10
⌀ | disposition_first_submitted_date
stringclasses 493
values | last_update_submitted_date
stringlengths 10
10
| study_first_submitted_qc_date
stringlengths 10
10
| study_first_posted_date
stringlengths 10
10
| study_first_posted_date_type
stringclasses 2
values | results_first_submitted_qc_date
stringlengths 10
10
⌀ | results_first_posted_date
stringlengths 10
10
⌀ | results_first_posted_date_type
stringclasses 2
values | disposition_first_submitted_qc_date
stringclasses 321
values | disposition_first_posted_date
stringclasses 478
values | disposition_first_posted_date_type
stringclasses 2
values | last_update_submitted_qc_date
stringlengths 10
10
| last_update_posted_date
stringlengths 10
10
| last_update_posted_date_type
stringclasses 2
values | start_month_year
stringlengths 7
10
⌀ | start_date_type
stringclasses 2
values | start_date
stringlengths 10
10
⌀ | verification_month_year
stringclasses 151
values | verification_date
stringclasses 151
values | completion_month_year
stringlengths 7
10
| completion_date_type
stringclasses 2
values | completion_date
stringlengths 10
10
| primary_completion_month_year
stringlengths 7
10
| primary_completion_date_type
stringclasses 2
values | primary_completion_date
stringlengths 10
10
| target_duration
float64 | study_type
stringclasses 1
value | acronym
stringlengths 2
14
⌀ | baseline_population
stringlengths 2
501
⌀ | brief_title
stringlengths 18
300
| official_title
stringlengths 28
563
⌀ | overall_status
stringclasses 4
values | last_known_status
float64 | phase
stringclasses 7
values | enrollment
float64 0
477k
| enrollment_type
stringclasses 2
values | source
stringlengths 3
107
| limitations_and_caveats
stringlengths 10
503
⌀ | number_of_arms
float64 1
27
⌀ | number_of_groups
float64 | why_stopped
stringlengths 3
252
⌀ | has_expanded_access
stringclasses 2
values | expanded_access_type_individual
float64 | expanded_access_type_intermediate
float64 | expanded_access_type_treatment
float64 | has_dmc
stringclasses 2
values | is_fda_regulated_drug
stringclasses 2
values | is_fda_regulated_device
stringclasses 2
values | is_unapproved_device
stringclasses 1
value | is_ppsd
float64 | is_us_export
stringclasses 2
values | biospec_retention
float64 | biospec_description
float64 | ipd_time_frame
stringclasses 442
values | ipd_access_criteria
stringclasses 465
values | ipd_url
stringclasses 124
values | plan_to_share_ipd
stringclasses 3
values | plan_to_share_ipd_description
stringlengths 3
998
⌀ | created_at
stringclasses 526
values | updated_at
stringclasses 526
values | source_class
stringclasses 8
values | delayed_posting
float64 | expanded_access_nctid
stringclasses 80
values | expanded_access_status_for_nctid
stringclasses 4
values | fdaaa801_violation
float64 | baseline_type_units_analyzed
stringclasses 11
values | patient_registry
float64 | completion_year
int64 2.02k
2.02k
| labels
float64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT03188185 | null | 2017-06-09 | 2021-02-19 | null | 2021-03-15 | 2017-06-14 | 2017-06-15 | ACTUAL | 2021-02-19 | 2021-03-15 | ACTUAL | null | null | null | 2021-03-15 | 2021-04-08 | ACTUAL | 2017-06-12 | ACTUAL | 2017-06-12 | 2021-03 | 2021-03-31 | 2020-03-05 | ACTUAL | 2020-03-05 | 2020-02-26 | ACTUAL | 2020-02-26 | null | INTERVENTIONAL | null | null | A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | COMPLETED | null | PHASE3 | 278 | ACTUAL | Alkermes, Inc. | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT03483103 | null | 2018-03-23 | 2022-09-23 | null | 2023-11-28 | 2018-03-23 | 2018-03-30 | ACTUAL | 2022-12-09 | 2022-12-29 | ACTUAL | null | null | null | 2023-11-28 | 2023-12-20 | ACTUAL | 2018-07-27 | ACTUAL | 2018-07-27 | 2023-11 | 2023-11-30 | 2022-12-01 | ACTUAL | 2022-12-01 | 2021-09-24 | ACTUAL | 2021-09-24 | null | INTERVENTIONAL | null | 74 participants were leukapheresed. | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) | COMPLETED | null | PHASE2 | 74 | ACTUAL | Juno Therapeutics, a Subsidiary of Celgene | null | 1 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT03535688 | null | 2018-04-03 | null | null | 2024-07-11 | 2018-05-14 | 2018-05-24 | ACTUAL | null | null | null | null | null | null | 2024-07-11 | 2024-07-15 | ACTUAL | 2018-03-30 | ACTUAL | 2018-03-30 | 2024-07 | 2024-07-31 | 2024-02-07 | ACTUAL | 2024-02-07 | 2024-02-07 | ACTUAL | 2024-02-07 | null | INTERVENTIONAL | null | null | D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain | D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain | TERMINATED | null | PHASE2 | 203 | ACTUAL | Northwestern University | null | 2 | null | Insufficient funding to complete the study | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT04978779 | null | 2021-07-15 | null | null | 2023-11-14 | 2021-07-20 | 2021-07-27 | ACTUAL | null | null | null | null | null | null | 2023-11-14 | 2023-11-18 | ACTUAL | 2021-12-16 | ACTUAL | 2021-12-16 | 2023-11 | 2023-11-30 | 2023-05-26 | ACTUAL | 2023-05-26 | 2023-05-26 | ACTUAL | 2023-05-26 | null | INTERVENTIONAL | null | null | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | An Open-label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP152 Monotherapy or Combination Therapy in Subjects With High-risk Chronic Lymphocytic Leukemia or Richter Syndrome | TERMINATED | null | PHASE1 | 6 | ACTUAL | Vincerx Pharma, Inc. | null | 2 | null | Slow enrollment | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT03317496 | null | 2017-09-29 | 2022-05-26 | null | 2023-08-04 | 2017-10-17 | 2017-10-23 | ACTUAL | 2022-05-26 | 2022-06-23 | ACTUAL | null | null | null | 2023-08-04 | 2023-08-29 | ACTUAL | 2017-12-21 | ACTUAL | 2017-12-21 | 2023-08 | 2023-08-31 | 2022-12-20 | ACTUAL | 2022-12-20 | 2021-06-07 | ACTUAL | 2021-06-07 | null | INTERVENTIONAL | null | null | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES | TERMINATED | null | PHASE1/PHASE2 | 67 | ACTUAL | Pfizer | The study was terminated since there was no need for further safety or efficacy data to be collected. The subjects having benefit from the investigational treatments have been moved to a continuation study NCT05059522 | 4 | null | The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522). | f | null | null | null | f | t | f | null | null | null | null | null | null | null | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests | YES | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04405102 | null | 2020-05-26 | null | null | 2024-02-16 | 2020-05-26 | 2020-05-28 | ACTUAL | null | null | null | null | null | null | 2024-02-16 | 2024-02-20 | ACTUAL | 2020-09-16 | ACTUAL | 2020-09-16 | 2024-02 | 2024-02-29 | 2022-05-12 | ACTUAL | 2022-05-12 | 2022-03-14 | ACTUAL | 2022-03-14 | null | INTERVENTIONAL | COZI | null | COVID-19 Ozanimod Intervention Study | A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial | TERMINATED | null | PHASE2 | 43 | ACTUAL | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | null | 2 | null | Screening was stopped by the Sponsor (43/48 participants enrolled), given the very low number of eligible patients (high vaccination rate and occurrence of the Omicron variant). The last patient randomized performed his follow-up visit. | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04464460 | null | 2020-07-08 | null | null | 2020-10-07 | 2020-07-08 | 2020-07-09 | ACTUAL | null | null | null | null | null | null | 2020-10-07 | 2020-10-08 | ACTUAL | 2020-09-25 | ESTIMATED | 2020-09-25 | 2020-10 | 2020-10-31 | 2020-10-30 | ESTIMATED | 2020-10-30 | 2020-10-30 | ESTIMATED | 2020-10-30 | null | INTERVENTIONAL | null | null | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults | A Randomized, Double-blind, Placebo-Controlled Multicenter Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 2 Different Intravenous Doses of TAK-671 for the Treatment of Coronavirus Disease 2019 in Adults | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Takeda | null | 2 | null | Business Decision (no enrollment) | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | YES | Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment. | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT05295589 | null | 2022-03-23 | null | null | 2023-09-22 | 2022-03-23 | 2022-03-25 | ACTUAL | null | null | null | null | null | null | 2023-09-22 | 2023-09-26 | ACTUAL | 2022-06-30 | ESTIMATED | 2022-06-30 | 2023-09 | 2023-09-30 | 2023-03-17 | ESTIMATED | 2023-03-17 | 2023-03-17 | ESTIMATED | 2023-03-17 | null | INTERVENTIONAL | null | null | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | National Cancer Institute (NCI) | null | 2 | null | Drug supply issues | f | null | null | null | f | t | f | null | null | null | null | null | null | null | https://grants.nih.gov/policy/sharing.htm | YES | NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page. | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | NIH | null | null | null | null | null | null | 2,023 | 0 |
NCT04871113 | null | 2021-04-28 | 2023-10-27 | null | 2024-09-18 | 2021-04-28 | 2021-05-04 | ACTUAL | 2023-10-27 | 2023-11-18 | ACTUAL | null | null | null | 2024-09-18 | 2024-10-15 | ACTUAL | 2021-06-22 | ACTUAL | 2021-06-22 | 2024-09 | 2024-09-30 | 2023-09-21 | ACTUAL | 2023-09-21 | 2022-10-27 | ACTUAL | 2022-10-27 | null | INTERVENTIONAL | null | null | A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults | A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults | COMPLETED | null | PHASE2 | 62 | ACTUAL | ViiV Healthcare | null | 10 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications. | Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months. | https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf | YES | GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf. | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT03483753 | null | 2018-02-05 | null | null | 2023-10-02 | 2018-03-29 | 2018-03-30 | ACTUAL | null | null | null | null | null | null | 2023-10-02 | 2023-10-05 | ACTUAL | 2019-01 | ESTIMATED | 2019-01-31 | 2023-10 | 2023-10-31 | 2023-10-02 | ACTUAL | 2023-10-02 | 2023-10-02 | ACTUAL | 2023-10-02 | null | INTERVENTIONAL | VANCSIII | null | Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery | Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery: a Randomized and Controlled Trial | WITHDRAWN | null | PHASE2/PHASE3 | 0 | ACTUAL | University of Sao Paulo | null | 2 | null | no funding for the study | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT00002874 | null | 1999-11-01 | 2017-06-06 | null | 2022-05-23 | 2003-01-26 | 2003-01-27 | ESTIMATED | 2017-07-18 | 2017-08-18 | ACTUAL | null | null | null | 2022-05-23 | 2022-06-15 | ACTUAL | 1998-02 | null | 1998-02-28 | 2022-05 | 2022-05-31 | 2022-05-20 | ACTUAL | 2022-05-20 | 2015-08 | ACTUAL | 2015-08-31 | null | INTERVENTIONAL | null | Eligible patients who have not withdrawn | Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy | A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR pT3N0 CARCINOMA OF THE PROSTATE | COMPLETED | null | PHASE3 | 840 | ACTUAL | Radiation Therapy Oncology Group | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | NETWORK | null | null | null | null | null | null | 2,022 | 1 |
NCT02504203 | null | 2015-07-20 | null | null | 2022-02-03 | 2015-07-20 | 2015-07-21 | ESTIMATED | null | null | null | null | null | null | 2022-02-03 | 2022-02-04 | ACTUAL | 2015-11 | null | 2015-11-30 | 2022-02 | 2022-02-28 | 2021-06 | ACTUAL | 2021-06-30 | 2021-06 | ACTUAL | 2021-06-30 | null | INTERVENTIONAL | BCGR | null | Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial | Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial | TERMINATED | null | PHASE4 | 2,332 | ACTUAL | Bandim Health Project | null | 2 | null | Due to fewer than expected children enrolled and lower than expected overall mortality rate. | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04203056 | null | 2019-12-16 | 2023-09-30 | null | 2023-11-04 | 2019-12-16 | 2019-12-18 | ACTUAL | 2023-11-04 | 2023-11-28 | ACTUAL | null | null | null | 2023-11-04 | 2023-11-28 | ACTUAL | 2019-12-16 | ACTUAL | 2019-12-16 | 2023-11 | 2023-11-30 | 2022-10-01 | ACTUAL | 2022-10-01 | 2022-10-01 | ACTUAL | 2022-10-01 | null | INTERVENTIONAL | APPRAISE | null | Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | TERMINATED | null | PHASE4 | 15 | ACTUAL | University of California, Los Angeles | null | 2 | null | Withdraw of financial support by industry collaborator | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04470427 | null | 2020-07-11 | 2023-12-21 | null | 2024-03-19 | 2020-07-11 | 2020-07-14 | ACTUAL | 2024-03-19 | 2024-03-21 | ACTUAL | null | null | null | 2024-03-19 | 2024-03-21 | ACTUAL | 2020-07-27 | ACTUAL | 2020-07-27 | 2024-03 | 2024-03-31 | 2022-12-29 | ACTUAL | 2022-12-29 | 2022-12-29 | ACTUAL | 2022-12-29 | null | INTERVENTIONAL | null | All randomized participants who received at least 1 dose of treatment. | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | COMPLETED | null | PHASE3 | 30,415 | ACTUAL | ModernaTX, Inc. | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT03325439 | null | 2017-10-25 | 2022-06-22 | null | 2024-04-04 | 2017-10-25 | 2017-10-30 | ACTUAL | 2023-04-20 | 2024-01-16 | ACTUAL | null | null | null | 2024-04-04 | 2024-04-08 | ACTUAL | 2019-05-07 | ACTUAL | 2019-05-07 | 2024-04 | 2024-04-30 | 2021-05-29 | ACTUAL | 2021-05-29 | 2020-09-03 | ACTUAL | 2020-09-03 | null | INTERVENTIONAL | null | Baseline Characteristics refer to the All Study Participants Screened Set which consisted of all study participants who had signed the Informed Consent form (ICF) and underwent the study inclusion and exclusion criteria of the current protocol. No eligible study participants were enrolled in the Confirmatory Cohorts. The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues. | A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures | A Multicenter, Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Neonates With Repeated Electroencephalographic Seizures | TERMINATED | null | PHASE3 | 9 | ACTUAL | UCB Pharma | No eligible study participants were enrolled in the Confirmatory Cohorts. The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues. | 1 | null | Terminated (The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.) | f | null | null | null | t | f | f | null | null | null | null | null | Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion. | Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. | https://vivli.org/ | YES | Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available. | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT03018730 | null | 2017-01-09 | 2022-06-02 | null | 2023-09-11 | 2017-01-10 | 2017-01-12 | ESTIMATED | 2022-06-02 | 2022-06-29 | ACTUAL | null | null | null | 2023-09-11 | 2023-09-13 | ACTUAL | 2017-05-17 | ACTUAL | 2017-05-17 | 2023-09 | 2023-09-30 | 2020-01-09 | ACTUAL | 2020-01-09 | 2019-12-17 | ACTUAL | 2019-12-17 | null | INTERVENTIONAL | null | null | Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) | An Open Label Study of the Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) | COMPLETED | null | PHASE3 | 22 | ACTUAL | Protalix | null | 1 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT05413642 | null | 2022-06-09 | null | null | 2024-02-12 | 2022-06-09 | 2022-06-10 | ACTUAL | null | null | null | null | null | null | 2024-02-12 | 2024-02-14 | ACTUAL | 2023-07-01 | ACTUAL | 2023-07-01 | 2024-02 | 2024-02-29 | 2024-02-06 | ACTUAL | 2024-02-06 | 2024-02-06 | ACTUAL | 2024-02-06 | null | INTERVENTIONAL | COVER-HOME | null | COVID-19 Algorithm Treatment at Home | Prevention of Hospitalization of Patients With Early COVID-19 by an Anti-inflammatory Drug-based Home-treatment Algorithm:a Three-months, Pragmatic, Cluster Randomized, Open-label, Blinded Endpoint (PROBE) Trial | WITHDRAWN | null | PHASE3 | 0 | ACTUAL | Mario Negri Institute for Pharmacological Research | null | 2 | null | Due to changes in the monitoring rules for SARS-CoV-2 and the dramatic reduction in COVID-19 cases, it became extremely difficult to recruit the required number of patients provided by the study protocol to meet the study's primary objective. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT03558724 | null | 2018-05-17 | null | null | 2024-04-14 | 2018-06-14 | 2018-06-15 | ACTUAL | null | null | null | null | null | null | 2024-04-14 | 2024-04-16 | ACTUAL | 2018-10-29 | ACTUAL | 2018-10-29 | 2024-04 | 2024-04-30 | 2022-10-11 | ACTUAL | 2022-10-11 | 2022-10-11 | ACTUAL | 2022-10-11 | null | INTERVENTIONAL | ORCA | null | Fluorescence Endoscopy of Esophageal Carcinoma | Fluorescence Molecular Endoscopy of Locally Advanced Esophageal Carcinoma Using Bevacizumab-800CW to Evaluate Dose Response After Neoadjuvant Chemoradiotherapy: a Single-center Feasibility Study. | TERMINATED | null | PHASE1 | 25 | ACTUAL | University Medical Center Groningen | null | 3 | null | Dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was established | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04289948 | null | 2018-09-03 | null | null | 2020-02-26 | 2020-02-26 | 2020-02-28 | ACTUAL | null | null | null | null | null | null | 2020-02-26 | 2020-02-28 | ACTUAL | 2019-03-01 | ESTIMATED | 2019-03-01 | 2020-02 | 2020-02-29 | 2022-09-01 | ESTIMATED | 2022-09-01 | 2022-06-01 | ESTIMATED | 2022-06-01 | null | INTERVENTIONAL | PDFI | null | Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes | Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes | WITHDRAWN | null | PHASE1/PHASE2 | 0 | ACTUAL | University Hospitals of Derby and Burton NHS Foundation Trust | null | 2 | null | Funding issues meant that development of the study was halted. | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04324840 | null | 2020-03-25 | null | null | 2024-07-25 | 2020-03-25 | 2020-03-27 | ACTUAL | null | null | null | null | null | null | 2024-07-25 | 2024-07-26 | ACTUAL | 2020-07-10 | ACTUAL | 2020-07-10 | 2024-07 | 2024-07-31 | 2024-07-09 | ACTUAL | 2024-07-09 | 2024-07-09 | ACTUAL | 2024-07-09 | null | INTERVENTIONAL | null | null | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma | TERMINATED | null | PHASE1 | 184 | ACTUAL | Celgene | null | 3 | null | Business objectives have changed | f | null | null | null | f | f | f | null | null | null | null | null | See Plan Description | See Plan Description | https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/ | YES | Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/ | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT05229900 | null | 2022-01-26 | null | null | 2023-12-22 | 2022-02-07 | 2022-02-08 | ACTUAL | null | null | null | null | null | null | 2023-12-22 | 2023-12-28 | ACTUAL | 2022-04-21 | ACTUAL | 2022-04-21 | 2023-12 | 2023-12-31 | 2023-12-13 | ACTUAL | 2023-12-13 | 2023-12-13 | ACTUAL | 2023-12-13 | null | INTERVENTIONAL | null | null | A Study of SGN-ALPV in Advanced Solid Tumors | A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors | TERMINATED | null | PHASE1 | 43 | ACTUAL | Seagen Inc. | null | 1 | null | Study closed due to portfolio prioritization | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT03173963 | null | 2017-05-27 | null | null | 2020-02-24 | 2017-06-01 | 2017-06-02 | ACTUAL | null | null | null | null | null | null | 2020-02-24 | 2020-02-25 | ACTUAL | 2017-05-27 | ACTUAL | 2017-05-27 | 2020-02 | 2020-02-29 | 2020-02-21 | ACTUAL | 2020-02-21 | 2020-02-21 | ACTUAL | 2020-02-21 | null | INTERVENTIONAL | null | null | Empaglifozin in Early Diabetic Kidney Disease | Empagliflozin in Early Diabetic Kidney Disease | WITHDRAWN | null | PHASE3 | 0 | ACTUAL | National Institutes of Health Clinical Center (CC) | null | 2 | null | Original drug sponsor withdrew from study, replacement sponsor not obtained. | f | null | null | null | null | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | NIH | null | null | null | null | null | null | 2,020 | 0 |
NCT03743194 | null | 2018-10-31 | 2023-08-30 | null | 2023-12-11 | 2018-11-13 | 2018-11-16 | ACTUAL | 2023-12-11 | 2023-12-29 | ACTUAL | null | null | null | 2023-12-11 | 2023-12-29 | ACTUAL | 2021-12-14 | ACTUAL | 2021-12-14 | 2023-12 | 2023-12-31 | 2022-03-14 | ACTUAL | 2022-03-14 | 2022-02-28 | ACTUAL | 2022-02-28 | null | INTERVENTIONAL | null | null | Pectoralis and Serratus Muscle Blocks | Pectoralis and Serratus Muscle Blocks for Analgesia After Minimally Invasive Cardiac Procedures | COMPLETED | null | PHASE4 | 210 | ACTUAL | The Cleveland Clinic | null | 2 | null | null | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,022 | 1 |
NCT05201001 | null | 2021-07-09 | null | null | 2023-09-07 | 2022-01-07 | 2022-01-21 | ACTUAL | null | null | null | null | null | null | 2023-09-07 | 2023-09-11 | ACTUAL | 2023-09-07 | ACTUAL | 2023-09-07 | 2022-04 | 2022-04-30 | 2023-09-07 | ACTUAL | 2023-09-07 | 2023-09-07 | ACTUAL | 2023-09-07 | null | INTERVENTIONAL | APX005M | null | APX005M in Patients With Recurrent Ovarian Cancer | An Early Phase Randomized Trial of APX005M in BRCAwt Patients With Recurrent Ovarian Cancer | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | null | 3 | null | IMP provider company (Apexigen) is sold, thus both IMP and grant is terminated | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | UNDECIDED | NSGO-CTU can be contacted | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT04051801 | null | 2019-07-19 | null | null | 2021-05-25 | 2019-08-07 | 2019-08-09 | ACTUAL | null | null | null | null | null | null | 2021-05-25 | 2021-05-28 | ACTUAL | 2021-05-25 | ACTUAL | 2021-05-25 | 2021-05 | 2021-05-31 | 2021-05-25 | ACTUAL | 2021-05-25 | 2021-05-25 | ACTUAL | 2021-05-25 | null | INTERVENTIONAL | null | null | Multiple Ascending Dose Putative Cognitive Enhancer VU319 | Multiple Ascending Dose Phase I Study of the M1 Positive Allosteric Modulator VU0467319 | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Vanderbilt University Medical Center | null | 6 | null | Further development has been outlicensed to Acadia Pharmaceuticals | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03010865 | null | 2016-12-28 | null | null | 2019-01-15 | 2017-01-03 | 2017-01-05 | ESTIMATED | null | null | null | null | null | null | 2019-01-15 | 2019-01-17 | ACTUAL | 2017-06-01 | ACTUAL | 2017-06-01 | 2017-06 | 2017-06-30 | 2020-02 | ESTIMATED | 2020-02-29 | 2019-12 | ESTIMATED | 2019-12-31 | null | INTERVENTIONAL | null | null | Sodium Butyrate For Improving Cognitive Function In Schizophrenia | Sodium Butyrate As A Treatment For Improving Cognitive Function In Schizophrenia | WITHDRAWN | null | PHASE2/PHASE3 | 0 | ACTUAL | Shanghai Mental Health Center | null | 2 | null | sponsor withdrew the funds because the smell of sodium butyrate made blinding impossible | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | UNDECIDED | Stanley foundation requests: Based on the terms of your award, Stanley Medical Research Institute (SMRI) now requires submission of the individual patient data from all SMRI funded studies. In order to make the process as efficient as possible and provide a secure location for study data, National Institute of Mental Health (NIMH) is graciously allowing SMRI access to their National Database for Clinical Trials (NDCT) to collect and house data. | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04760626 | null | 2021-02-17 | null | 2023-08-10 | 2024-08-06 | 2021-02-17 | 2021-02-18 | ACTUAL | null | null | null | null | 2023-08-15 | ACTUAL | 2024-08-06 | 2024-08-07 | ACTUAL | 2021-03-01 | ACTUAL | 2021-03-01 | 2024-08 | 2024-08-31 | 2022-08-29 | ACTUAL | 2022-08-29 | 2022-08-12 | ACTUAL | 2022-08-12 | null | INTERVENTIONAL | ONWARDS 5 | null | A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before | Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting | COMPLETED | null | PHASE3 | 1,085 | ACTUAL | Novo Nordisk A/S | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | http://novonordisk-trials.com | YES | According to the Novo Nordisk disclosure commitment on novonordisk-trials.com | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT03941483 | null | 2019-05-06 | 2022-07-23 | null | 2023-04-20 | 2019-05-06 | 2019-05-08 | ACTUAL | 2022-09-08 | 2022-10-04 | ACTUAL | null | null | null | 2023-04-20 | 2023-04-24 | ACTUAL | 2019-11-01 | ACTUAL | 2019-11-01 | 2023-04 | 2023-04-30 | 2021-10-20 | ACTUAL | 2021-10-20 | 2021-07-26 | ACTUAL | 2021-07-26 | null | INTERVENTIONAL | null | ASP1128 and Placebo: Full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study treatment.~Observational Cohort: NC negative participants who were enrolled in the observational cohort. | Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery | A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery | COMPLETED | null | PHASE2 | 351 | ACTUAL | Astellas Pharma Inc | null | 3 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data. | Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement. | https://clinicalstudydatarequest.com | YES | Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com. | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT03679884 | null | 2018-09-19 | 2022-01-07 | null | 2022-02-07 | 2018-09-20 | 2018-09-21 | ACTUAL | 2022-02-07 | 2022-03-02 | ACTUAL | null | null | null | 2022-02-07 | 2022-03-02 | ACTUAL | 2018-10-09 | ACTUAL | 2018-10-09 | 2022-02 | 2022-02-28 | 2021-02-22 | ACTUAL | 2021-02-22 | 2021-02-22 | ACTUAL | 2021-02-22 | null | INTERVENTIONAL | null | These are the participants included in the FAS. The discrepancy with previous table (Participant Flow) is due to 3 subjects on FAS (2 on daridorexant 25 mg and 1 on ex-placebo/ daridorexant 25 mg) not starting DB treatment. | Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep | Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Three Doses, 40-week Extension to Studies ID-078A301 and ID-078A302 to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder | COMPLETED | null | PHASE3 | 804 | ACTUAL | Idorsia Pharmaceuticals Ltd. | null | 5 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT02478502 | null | 2014-08-28 | null | null | 2024-02-01 | 2015-06-22 | 2015-06-23 | ESTIMATED | null | null | null | null | null | null | 2024-02-01 | 2024-02-02 | ACTUAL | 2015-06 | null | 2015-06-30 | 2024-02 | 2024-02-29 | 2022-12-31 | ACTUAL | 2022-12-31 | 2022-12-31 | ACTUAL | 2022-12-31 | null | INTERVENTIONAL | null | null | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer | Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell | TERMINATED | null | PHASE2 | 14 | ACTUAL | University Hospital, Akershus | null | 1 | null | Insufficient recruitment | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04602000 | null | 2020-10-18 | 2022-05-10 | null | 2022-06-27 | 2020-10-23 | 2020-10-26 | ACTUAL | 2022-06-27 | 2022-07-20 | ACTUAL | null | null | null | 2022-06-27 | 2022-07-20 | ACTUAL | 2020-10-05 | ACTUAL | 2020-10-05 | 2022-06 | 2022-06-30 | 2021-10-20 | ACTUAL | 2021-10-20 | 2021-05-21 | ACTUAL | 2021-05-21 | null | INTERVENTIONAL | null | null | A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection | A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With SARS-CoV-2 Infection | COMPLETED | null | PHASE2/PHASE3 | 1,642 | ACTUAL | Celltrion | null | 5 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT03298061 | null | 2017-09-27 | 2024-02-14 | null | 2024-02-14 | 2017-09-27 | 2017-09-29 | ACTUAL | 2024-02-14 | 2024-03-12 | ACTUAL | null | null | null | 2024-02-14 | 2024-03-12 | ACTUAL | 2015-04-14 | ACTUAL | 2015-04-14 | 2024-02 | 2024-02-29 | 2023-02-16 | ACTUAL | 2023-02-16 | 2023-02-16 | ACTUAL | 2023-02-16 | null | INTERVENTIONAL | null | null | Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 | Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy) | COMPLETED | null | PHASE3 | 100 | ACTUAL | GlaxoSmithKline | null | 1 | null | null | t | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | NCT00244686 | NO_LONGER_AVAILABLE | null | null | null | 2,023 | 1 |
NCT06119529 | null | 2023-11-01 | null | null | 2024-07-24 | 2023-11-01 | 2023-11-07 | ACTUAL | null | null | null | null | null | null | 2024-07-24 | 2024-07-25 | ACTUAL | 2023-11-01 | ACTUAL | 2023-11-01 | 2024-07 | 2024-07-31 | 2024-04-08 | ACTUAL | 2024-04-08 | 2024-04-08 | ACTUAL | 2024-04-08 | null | INTERVENTIONAL | null | null | A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis | A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3872386 in Healthy Participants, a Multiple-Ascending Dose Study of LY3872386 in Patients With Atopic Dermatitis, and an Open-Label Multiple-Dose Evaluation of the Safety and Tolerability of Prednisone in Healthy Participants. | TERMINATED | null | PHASE1 | 18 | ACTUAL | Eli Lilly and Company | null | 4 | null | Based on emerging nonclinical data, the study was terminated. | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT04433078 | null | 2020-06-10 | null | null | 2021-04-13 | 2020-06-12 | 2020-06-16 | ACTUAL | null | null | null | null | null | null | 2021-04-13 | 2021-04-19 | ACTUAL | 2020-06-22 | ACTUAL | 2020-06-22 | 2021-04 | 2021-04-30 | 2021-04-13 | ACTUAL | 2021-04-13 | 2021-04-13 | ACTUAL | 2021-04-13 | null | INTERVENTIONAL | STORM | null | RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM | RepurpoSing Old Drugs TO SuppRess a Modern Threat: The STORM Trial | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Temple University | null | 2 | null | No Participants Enrolled | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 18:03:23.937454 | 2024-10-15 18:03:23.937454 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04600323 | null | 2020-10-19 | null | null | 2024-05-07 | 2020-10-19 | 2020-10-23 | ACTUAL | null | null | null | null | null | null | 2024-05-07 | 2024-05-08 | ACTUAL | 2021-02-01 | ACTUAL | 2021-02-01 | 2024-05 | 2024-05-31 | 2023-08-30 | ACTUAL | 2023-08-30 | 2023-08-30 | ACTUAL | 2023-08-30 | null | INTERVENTIONAL | null | null | Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD | Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD | COMPLETED | null | EARLY_PHASE1 | 34 | ACTUAL | University of Colorado, Denver | null | 2 | null | null | f | null | null | null | t | t | f | null | null | f | null | null | At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use. The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines. | null | null | YES | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT03329001 | null | 2017-10-23 | 2022-12-19 | null | 2024-07-17 | 2017-10-30 | 2017-11-01 | ACTUAL | 2023-11-13 | 2024-04-26 | ACTUAL | null | null | null | 2024-07-17 | 2024-07-25 | ACTUAL | 2017-12-04 | ACTUAL | 2017-12-04 | 2024-07 | 2024-07-31 | 2023-06-15 | ACTUAL | 2023-06-15 | 2021-12-30 | ACTUAL | 2021-12-30 | null | INTERVENTIONAL | null | Baseline characteristics were presented for Safety Population, all participants who received any amount of niraparib during the PK phase of study. | Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule | An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors | COMPLETED | null | PHASE1 | 236 | ACTUAL | Tesaro, Inc. | null | 6 | null | null | null | null | null | null | f | t | f | null | null | null | null | null | Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications. | Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months. | https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf | YES | GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT04167670 | null | 2019-11-15 | 2022-03-09 | null | 2022-03-09 | 2019-11-15 | 2019-11-19 | ACTUAL | 2022-03-09 | 2022-04-05 | ACTUAL | null | null | null | 2022-03-09 | 2022-04-05 | ACTUAL | 2019-12-10 | ACTUAL | 2019-12-10 | 2022-03 | 2022-03-31 | 2021-03-18 | ACTUAL | 2021-03-18 | 2021-03-10 | ACTUAL | 2021-03-10 | null | INTERVENTIONAL | null | Randomized Set - All participants randomly assigned to receive study drug regardless of whether or not they received a dose of study drug during the study. | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection | A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg Daily in Patients With Helicobacter Pylori Infection | COMPLETED | null | PHASE3 | 1,046 | ACTUAL | Phathom Pharmaceuticals, Inc. | null | 3 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT02960906 | null | 2016-08-18 | null | null | 2021-04-22 | 2016-11-08 | 2016-11-10 | ESTIMATED | null | null | null | null | null | null | 2021-04-22 | 2021-04-26 | ACTUAL | 2017-05-31 | ACTUAL | 2017-05-31 | 2021-04 | 2021-04-30 | 2021-02-15 | ACTUAL | 2021-02-15 | 2021-02-15 | ACTUAL | 2021-02-15 | null | INTERVENTIONAL | BIONIKK | null | A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer | A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer | COMPLETED | null | PHASE2 | 200 | ACTUAL | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | null | 8 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT02489201 | null | 2015-06-24 | null | null | 2023-06-13 | 2015-07-01 | 2015-07-02 | ESTIMATED | null | null | null | null | null | null | 2023-06-13 | 2023-06-15 | ACTUAL | 2015-07-21 | ACTUAL | 2015-07-21 | 2023-06 | 2023-06-30 | 2020-10-29 | ACTUAL | 2020-10-29 | 2020-10-29 | ACTUAL | 2020-10-29 | null | INTERVENTIONAL | null | null | A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer | A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy | TERMINATED | null | PHASE1/PHASE2 | 19 | ACTUAL | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | null | 1 | null | Corporate policy adjustments | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT05028361 | null | 2021-08-30 | 2024-01-23 | null | 2024-02-20 | 2021-08-30 | 2021-08-31 | ACTUAL | 2024-02-20 | 2024-03-19 | ACTUAL | null | null | null | 2024-02-20 | 2024-03-19 | ACTUAL | 2021-10-04 | ACTUAL | 2021-10-04 | 2024-02 | 2024-02-29 | 2023-06-15 | ACTUAL | 2023-06-15 | 2023-03-03 | ACTUAL | 2023-03-03 | null | INTERVENTIONAL | null | null | Simultaneous mRNA COVID-19 and IIV4 Vaccination Study | Safety of Simultaneous Versus Sequential Administration of mRNA COVID-19 Vaccines and Quadrivalent Inactivated Influenza (IIV4) in Adults, Adolescents and Children: A Randomized Observer Blinded Study | COMPLETED | null | PHASE4 | 348 | ACTUAL | Duke University | null | 2 | null | null | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT02930941 | null | 2016-10-10 | 2021-08-24 | null | 2021-11-03 | 2016-10-11 | 2016-10-12 | ESTIMATED | 2021-11-03 | 2021-11-30 | ACTUAL | null | null | null | 2021-11-03 | 2021-11-30 | ACTUAL | 2016-02 | null | 2016-02-29 | 2021-11 | 2021-11-30 | 2020-12-31 | ACTUAL | 2020-12-31 | 2020-12-31 | ACTUAL | 2020-12-31 | null | INTERVENTIONAL | null | null | Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department | Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department | TERMINATED | null | PHASE4 | 35 | ACTUAL | University of California, Davis | Coronavirus Disease 2019 (COVID-19) pandemic significantly impacted the ability to enroll patients; early termination leading to a small number of patients; single-center study; | 2 | null | Terminate due to slow enrollment rate. | f | null | null | null | t | t | null | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03403517 | null | 2018-01-05 | 2020-12-08 | null | 2020-12-08 | 2018-01-11 | 2018-01-18 | ACTUAL | 2020-12-08 | 2021-01-05 | ACTUAL | null | null | null | 2020-12-08 | 2021-01-05 | ACTUAL | 2017-12-11 | ACTUAL | 2017-12-11 | 2020-12 | 2020-12-31 | 2020-09-28 | ACTUAL | 2020-09-28 | 2020-08-28 | ACTUAL | 2020-08-28 | null | INTERVENTIONAL | STEREO | null | Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period | High Dose Steroids for Liver Resection - Effect on Complications and Endothelial Function in the Immediate Postoperative Phase - a Randomized, Doubleblind, Controlled Trial | COMPLETED | null | PHASE4 | 174 | ACTUAL | Rigshospitalet, Denmark | null | 2 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT02911467 | null | 2016-09-19 | null | null | 2020-07-22 | 2016-09-20 | 2016-09-22 | ESTIMATED | null | null | null | null | null | null | 2020-07-22 | 2020-07-24 | ACTUAL | 2016-11-08 | ACTUAL | 2016-11-08 | 2020-07 | 2020-07-31 | 2020-07-20 | ACTUAL | 2020-07-20 | 2020-07-20 | ACTUAL | 2020-07-20 | null | INTERVENTIONAL | MR | null | Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer | Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Predictive Biomarker of Response to Androgen Signaling Inhibitors in Castration-Resistant Prostate Cancer | TERMINATED | null | PHASE1 | 8 | ACTUAL | University of California, San Francisco | null | 1 | null | Low Accrual | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04398134 | null | 2020-05-18 | 2022-08-03 | null | 2022-08-30 | 2020-05-18 | 2020-05-21 | ACTUAL | 2022-08-03 | 2022-08-26 | ACTUAL | null | null | null | 2022-08-30 | 2022-09-15 | ACTUAL | 2020-08-28 | ACTUAL | 2020-08-28 | 2022-08 | 2022-08-31 | 2021-12-28 | ACTUAL | 2021-12-28 | 2021-10-14 | ACTUAL | 2021-10-14 | null | INTERVENTIONAL | null | null | A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection | TERMINATED | null | PHASE2 | 88 | ACTUAL | Assembly Biosciences | Study ABI-H2158-201 was terminated early due to alanine aminotransferase (ALT) elevations among study participants who received ABI-H2158 (and not among those who received PBO). Further details on these events are described in the results section below. In the absence of an alternative etiology for the ALT elevations, further clinical development of ABI-H2158 was terminated by the Sponsor. | 2 | null | Study stopped due to a safety signal of drug-induced liver injury in subjects receiving 2158 | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04913675 | null | 2021-05-27 | 2022-11-08 | null | 2024-02-15 | 2021-06-02 | 2021-06-04 | ACTUAL | 2023-05-01 | 2023-05-26 | ACTUAL | null | null | null | 2024-02-15 | 2024-03-07 | ACTUAL | 2021-06-10 | ACTUAL | 2021-06-10 | 2024-01 | 2024-01-31 | 2023-03-24 | ACTUAL | 2023-03-24 | 2022-07-19 | ACTUAL | 2022-07-19 | null | INTERVENTIONAL | null | Baseline characteristics were reported for Safety Population for Main Study and Safety Sub-study. | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | A Phase 3 Randomized, Multi-center, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Monoclonal Antibody VIR-7831 (Sotrovimab) Given Intramuscularly Versus Intravenously for the Treatment of Mild/Moderate Coronavirus Disease 2019 (COVID-19) in High-risk Non-hospitalized Patients; Safety Substudy Assessing the Safety and Tolerability of Single Ascending Dose Monoclonal Antibody VIR-7831 | TERMINATED | null | PHASE3 | 1,065 | ACTUAL | Vir Biotechnology, Inc. | The pre-specified daily imputation resulted in overly high inflation in the estimated progression rates for missing data. To reduce this bias and to account for progression history, weekly imputation was used for final conclusions. | 7 | null | The safety sub-study was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT03381833 | null | 2017-12-12 | null | null | 2021-07-28 | 2017-12-20 | 2017-12-22 | ACTUAL | null | null | null | null | null | null | 2021-07-28 | 2021-07-29 | ACTUAL | 2017-11-30 | ACTUAL | 2017-11-30 | 2021-07 | 2021-07-31 | 2020-01-14 | ACTUAL | 2020-01-14 | 2019-12-03 | ACTUAL | 2019-12-03 | null | INTERVENTIONAL | null | null | A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia | A Multi-Center, Randomized, Open-Label, Parallel-Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia | TERMINATED | null | PHASE2 | 84 | ACTUAL | La Jolla Pharmaceutical Company | null | 2 | null | Terminated early for lack of efficacy as determined by interim endpoint analyses | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT05993143 | null | 2023-08-08 | null | null | 2023-08-10 | 2023-08-10 | 2023-08-15 | ACTUAL | null | null | null | null | null | null | 2023-08-10 | 2023-08-15 | ACTUAL | 2021-01-18 | ACTUAL | 2021-01-18 | 2023-08 | 2023-08-31 | 2021-07-21 | ACTUAL | 2021-07-21 | 2021-07-21 | ACTUAL | 2021-07-21 | null | INTERVENTIONAL | null | null | Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50 | A Multicentre, Phase III, Double-blind, Randomised, Parallel, Placebo-controlled Trial to Assess Efficacy and Safety of Early Administration of Ivermectin During 3 Consecutive Days to Prevent SARS CoV-2 (COVID-19) Hospitalisation in Adults Older Than 50 Years of Age | TERMINATED | null | PHASE3 | 249 | ACTUAL | Insud Pharma | null | 2 | null | Study was stopped because no statistically significant difference was observed in the interim analysis. With high vaccine rates in those over 50 and an expected low incidence, it would not be feasible to complete recruitment within a short period. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04487431 | null | 2020-07-23 | null | null | 2023-01-24 | 2020-07-23 | 2020-07-27 | ACTUAL | null | null | null | null | null | null | 2023-01-24 | 2023-01-26 | ACTUAL | 2020-08-05 | ACTUAL | 2020-08-05 | 2023-01 | 2023-01-31 | 2021-02-11 | ACTUAL | 2021-02-11 | 2020-09-30 | ACTUAL | 2020-09-30 | null | INTERVENTIONAL | null | null | A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B) | Single-center, Open-label, Non-placebo-controlled, Single-dose Study in Healthy Male Participants to Determine the Pharmacokinetics of BAY 1817080 Oral Solution (Part A) and to Investigate the Pharmacokinetics, Metabolic Disposition and Mass Balance of [14C]BAY 1817080 Oral Solution (Part B) | COMPLETED | null | PHASE1 | 14 | ACTUAL | Bayer | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal. | 2024-10-15 18:03:23.937454 | 2024-10-15 18:03:23.937454 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT04115059 | null | 2019-10-02 | 2022-04-01 | null | 2023-09-12 | 2019-10-02 | 2019-10-03 | ACTUAL | 2023-09-12 | 2024-03-21 | ACTUAL | null | null | null | 2023-09-12 | 2024-03-21 | ACTUAL | 2019-11-04 | ACTUAL | 2019-11-04 | 2023-09 | 2023-09-30 | 2021-12-31 | ACTUAL | 2021-12-31 | 2021-12-31 | ACTUAL | 2021-12-31 | null | INTERVENTIONAL | null | null | Dasatinib In Waldenström Macroglobulinemia | Dasatinib in Patients With Waldenström Macroglobulinemia (WM) Progressing on Ibrutinib | TERMINATED | null | PHASE1 | 3 | ACTUAL | Dana-Farber Cancer Institute | null | 1 | null | Lack of efficacy | f | null | null | null | t | t | f | null | null | null | null | null | Data can be shared no earlier than 1 year following the date of publication | Contact the Belfer Office for Dana-Farber Innovations (BODFI) at [email protected] | null | YES | The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research. | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03852576 | null | 2019-02-20 | null | null | 2022-11-17 | 2019-02-21 | 2019-02-25 | ACTUAL | null | null | null | null | null | null | 2022-11-17 | 2022-11-22 | ACTUAL | 2019-05-09 | ACTUAL | 2019-05-09 | 2022-11 | 2022-11-30 | 2020-11-18 | ACTUAL | 2020-11-18 | 2020-11-18 | ACTUAL | 2020-11-18 | null | INTERVENTIONAL | null | null | Phase 1B Study of KSP/QRH Dimer for Detection of Neoplasia in the Esophagus | Phase 1B In-vivo Study of KSP/QRH Heptapeptide Dimer for Detection of Neoplasia in the Esophagus | TERMINATED | null | PHASE1 | 38 | ACTUAL | University of Michigan | null | 1 | null | Study had to be terminated for lack of dimer and inability to produce more at this time. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-17 02:48:38.241354 | 2024-10-17 02:48:38.241354 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04601285 | null | 2020-10-12 | null | null | 2023-07-04 | 2020-10-19 | 2020-10-23 | ACTUAL | null | null | null | null | null | null | 2023-07-04 | 2023-07-06 | ACTUAL | 2020-10-28 | ACTUAL | 2020-10-28 | 2023-07 | 2023-07-31 | 2023-06-14 | ACTUAL | 2023-06-14 | 2023-06-14 | ACTUAL | 2023-06-14 | null | INTERVENTIONAL | null | null | A Phase I Study of JS108 in Patients With Advanced Solid Tumors | A Phase I, Open-label, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Recombinant Humanized Anti-Trop2 mAb-Tub196 Conjugate in Patients With Advanced Solid Tumors. | TERMINATED | null | PHASE1 | 25 | ACTUAL | Shanghai Junshi Bioscience Co., Ltd. | null | 1 | null | Sponsor has adjusted study development plan and terminated this clinical study. | f | null | null | null | null | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT02949934 | null | 2016-10-26 | 2022-03-21 | null | 2023-05-11 | 2016-10-27 | 2016-10-31 | ESTIMATED | 2022-03-21 | 2022-04-15 | ACTUAL | null | null | null | 2023-05-11 | 2023-06-09 | ACTUAL | 2016-05-01 | ACTUAL | 2016-05-01 | 2023-05 | 2023-05-31 | 2021-04-13 | ACTUAL | 2021-04-13 | 2021-04-13 | ACTUAL | 2021-04-13 | null | INTERVENTIONAL | null | Non-treatment-seeking individuals between the ages of 21 and 40 with DSM-5 diagnosed Alcohol Use Disorder. | Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control | null | COMPLETED | null | PHASE2 | 90 | ACTUAL | Medical University of South Carolina | null | 6 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT04847921 | null | 2021-04-13 | null | null | 2023-10-17 | 2021-04-13 | 2021-04-19 | ACTUAL | null | null | null | null | null | null | 2023-10-17 | 2023-10-19 | ACTUAL | 2021-04-30 | ACTUAL | 2021-04-30 | 2023-10 | 2023-10-31 | 2023-10-05 | ACTUAL | 2023-10-05 | 2023-10-05 | ACTUAL | 2023-10-05 | null | INTERVENTIONAL | SUDDEN-OUT | null | Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition | Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive Infections | TERMINATED | null | PHASE2/PHASE3 | 11 | ACTUAL | University of Colorado, Denver | null | 1 | null | Delays in recruitment due to COVID-19 and higher than acceptable loss to followup. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03478878 | null | 2018-03-21 | 2024-05-03 | null | 2024-07-05 | 2018-03-24 | 2018-03-27 | ACTUAL | 2024-06-06 | 2024-07-03 | ACTUAL | null | null | null | 2024-07-05 | 2024-07-30 | ACTUAL | 2018-05-14 | ACTUAL | 2018-05-14 | 2023-12 | 2023-12-31 | 2022-06-17 | ACTUAL | 2022-06-17 | 2022-06-17 | ACTUAL | 2022-06-17 | null | INTERVENTIONAL | null | null | Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation | An Investigation of Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation | COMPLETED | null | EARLY_PHASE1 | 9 | ACTUAL | National Institutes of Health Clinical Center (CC) | null | 1 | null | null | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | NIH | null | null | null | null | null | null | 2,022 | 1 |
NCT03174522 | null | 2017-05-31 | null | null | 2023-03-14 | 2017-06-01 | 2017-06-02 | ACTUAL | null | null | null | null | null | null | 2023-03-14 | 2023-03-16 | ACTUAL | 2017-04-25 | ACTUAL | 2017-04-25 | 2023-03 | 2023-03-31 | 2023-02-13 | ACTUAL | 2023-02-13 | 2023-02-13 | ACTUAL | 2023-02-13 | null | INTERVENTIONAL | null | null | The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM | The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial | TERMINATED | null | PHASE3 | 49 | ACTUAL | Ixaka Ltd | null | 2 | null | Independent Data Monitoring Committee recommendation to stop due to futility | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT03854227 | null | 2019-02-15 | null | null | 2022-11-17 | 2019-02-22 | 2019-02-26 | ACTUAL | null | null | null | null | null | null | 2022-11-17 | 2022-11-22 | ACTUAL | 2019-03-14 | ACTUAL | 2019-03-14 | 2022-11 | 2022-11-30 | 2022-04-27 | ACTUAL | 2022-04-27 | 2022-04-27 | ACTUAL | 2022-04-27 | null | INTERVENTIONAL | null | null | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939999 (PRMT5 INHIBITOR) IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, HEAD AND NECK SQUAMOUS CELL CARCINOMA, ESOPHAGEAL CANCER, ENDOMETRIAL CANCER, CERVICAL CANCER AND BLADDER CANCER | TERMINATED | null | PHASE1 | 54 | ACTUAL | Pfizer | null | 6 | null | The study has been terminated based on a strategic evaluation within the current Pfizer oncology portfolio. This decision is not due to any safety concerns or requests from any regulatory authorities. | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT03770455 | null | 2018-10-05 | 2021-12-17 | null | 2024-06-26 | 2018-12-07 | 2018-12-10 | ACTUAL | 2021-12-17 | 2022-01-18 | ACTUAL | null | null | null | 2024-06-26 | 2024-07-09 | ACTUAL | 2019-01-25 | ACTUAL | 2019-01-25 | 2024-06 | 2024-06-30 | 2021-01-07 | ACTUAL | 2021-01-07 | 2020-12-17 | ACTUAL | 2020-12-17 | null | INTERVENTIONAL | null | null | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | PDL-1 Inhibition With Avelumab and Concurrent Second-generation ADT in African Americans With Castrate-resistant Metastatic Prostate Cancer | TERMINATED | null | PHASE2 | 8 | ACTUAL | Tulane University | Study did not reach target number of participants needed to reach target power for statistically reliable results due to poor recruitment during Coronavirus Disease 2019 (COVID-19) pandemic and early termination of study.~Study closed early due to safety concerns regarding rapid clinical progression of several participants, therefore, the secondary outcome measures were not analyzed and no data was reported for those outcome measures, so they were deleted from the study record. | 1 | null | Early signs of progression and learned experience that the assumed time period between psa progression and radiographic progression was shorter than expected | f | null | null | null | f | t | f | null | null | null | null | null | 2022 | To be determined pending publication | null | YES | all collected IPD, all IPD that underlie results in a publication | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03624036 | null | 2018-08-07 | 2022-02-14 | null | 2023-10-31 | 2018-08-07 | 2018-08-09 | ACTUAL | 2022-05-06 | 2022-05-10 | ACTUAL | null | null | null | 2023-10-31 | 2023-11-18 | ACTUAL | 2018-11-15 | ACTUAL | 2018-11-15 | 2023-10 | 2023-10-31 | 2022-11-18 | ACTUAL | 2022-11-18 | 2021-02-12 | ACTUAL | 2021-02-12 | null | INTERVENTIONAL | ZUMA-8 | Safety Analysis Set included all participants who were treated with any dose of brexucabtagene autoleucel. | Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | TERMINATED | null | PHASE1 | 16 | ACTUAL | Gilead Sciences | null | 5 | null | Development program terminated | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04518410 | null | 2020-08-17 | 2023-04-07 | null | 2024-08-01 | 2020-08-18 | 2020-08-19 | ACTUAL | 2023-07-06 | 2023-07-27 | ACTUAL | null | null | null | 2024-08-01 | 2024-08-02 | ACTUAL | 2020-08-19 | ACTUAL | 2020-08-19 | 2024-08 | 2024-08-31 | 2023-06-20 | ACTUAL | 2023-06-20 | 2022-04-07 | ACTUAL | 2022-04-07 | null | INTERVENTIONAL | null | Total MITT Population=Randomized and Treated and included in analysis = All with Randomization Date - Randomized Not Treated-Randomized screen failed - Excluded from analysis - Dual enrollment = 4044 - 54 - 2 - 252 - 1~All participants were considered to be separately enrolled participants for subsequent phases of the study.~BRII arms included pooled participants from Phase 2/Phase 3 to complete a Phase 3 analysis. | ACTIV-2: A Study for Outpatients With COVID-19 | Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID) | COMPLETED | null | PHASE2/PHASE3 | 4,044 | ACTUAL | National Institute of Allergy and Infectious Diseases (NIAID) | null | 25 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | NIAID OCICB requires a Data Use Agreement be signed by investigators seeking to obtain the PUD. | https://accessclinicaldata.niaid.nih.gov/study-viewer/clinical_trials | YES | Individual patient level data are available from ACTIV-2 clinical trial in accessclinicaldata@NIAID, a NIAID cloud-based secure controlled access data platform that enables sharing of and access to data sets from clinical trials for basic and clinical research and requires a data access request and a signed data use agreement. | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | NIH | null | null | null | null | null | null | 2,023 | 1 |
NCT03634150 | null | 2018-06-20 | null | null | 2021-10-18 | 2018-08-14 | 2018-08-16 | ACTUAL | null | null | null | null | null | null | 2021-10-18 | 2021-10-26 | ACTUAL | 2018-09-06 | ACTUAL | 2018-09-06 | 2021-10 | 2021-10-31 | 2020-04-21 | ACTUAL | 2020-04-21 | 2020-04-21 | ACTUAL | 2020-04-21 | null | INTERVENTIONAL | null | null | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | A Phase 1b, Open-Label, Dose-Confirmation Study Evaluating the Safety, and Clinical Effects of Intravenously Administered Nerofe™ in Combination With Doxorubicin, In Subjects With Metastatic Ovarian Cancer and Triple Negative Breast Cancer | WITHDRAWN | null | PHASE1/PHASE2 | 0 | ACTUAL | Immune System Key Ltd | null | 1 | null | Patients were screened but not enrolled | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT03759184 | null | 2018-11-28 | 2022-02-15 | null | 2022-03-11 | 2018-11-28 | 2018-11-29 | ACTUAL | 2022-02-15 | 2022-03-10 | ACTUAL | null | null | null | 2022-03-11 | 2022-03-22 | ACTUAL | 2019-07-11 | ACTUAL | 2019-07-11 | 2022-03 | 2022-03-31 | 2021-10-22 | ACTUAL | 2021-10-22 | 2019-12-15 | ACTUAL | 2019-12-15 | null | INTERVENTIONAL | null | null | Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | TERMINATED | null | PHASE1 | 1 | ACTUAL | National Institutes of Health Clinical Center (CC) | null | 2 | null | The study was closed after \> 1 year of inactivity. | f | null | null | null | f | t | f | null | null | null | null | null | Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genome Data Sharing (GDS) plan for as long as database is active. | Clinical data will be made available via subscription to Biomedical Translational Research (BTRIS) and with the permission of the study principal investigator (PI).~Genomic data are made available via database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians. | null | YES | All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | NIH | null | null | null | null | null | null | 2,021 | 0 |
NCT02827968 | null | 2016-06-29 | null | null | 2021-05-31 | 2016-07-06 | 2016-07-11 | ESTIMATED | null | null | null | null | null | null | 2021-05-31 | 2021-06-02 | ACTUAL | 2017-01-13 | ACTUAL | 2017-01-13 | 2021-03 | 2021-03-31 | 2020-12 | ACTUAL | 2020-12-31 | 2020-08 | ACTUAL | 2020-08-31 | null | INTERVENTIONAL | null | null | Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors | A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors | COMPLETED | null | PHASE1 | 28 | ACTUAL | 3D Medicines | null | 1 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT04441398 | null | 2020-06-18 | null | null | 2022-10-26 | 2020-06-19 | 2020-06-22 | ACTUAL | null | null | null | null | null | null | 2022-10-26 | 2022-10-28 | ACTUAL | 2020-07 | ESTIMATED | 2020-07-31 | 2022-10 | 2022-10-31 | 2020-09 | ESTIMATED | 2020-09-30 | 2020-09 | ESTIMATED | 2020-09-30 | null | INTERVENTIONAL | null | null | Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients | Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita | WITHDRAWN | null | PHASE2/PHASE3 | 0 | ACTUAL | Azidus Brasil | null | 2 | null | Sponsor's strategic decision | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public. | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04925934 | null | 2021-05-04 | 2024-06-07 | 2024-02-26 | 2024-07-21 | 2021-06-08 | 2021-06-14 | ACTUAL | 2024-07-21 | 2024-07-23 | ACTUAL | null | 2024-07-23 | ACTUAL | 2024-07-21 | 2024-07-23 | ACTUAL | 2021-05-28 | ACTUAL | 2021-05-28 | 2024-07 | 2024-07-31 | 2023-06-09 | ACTUAL | 2023-06-09 | 2023-05-16 | ACTUAL | 2023-05-16 | null | INTERVENTIONAL | RECAST SLE | Full analysis set (FAS): included all randomized participants who received any dose of investigational product (IP). Participants were analyzed according to the treatment randomized. | Study of VIB7734 for the Treatment of Moderate to Severely Active SLE | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus | COMPLETED | null | PHASE2 | 214 | ACTUAL | Amgen | null | 3 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT04269395 | null | 2020-02-10 | 2023-05-27 | null | 2023-09-15 | 2020-02-12 | 2020-02-13 | ACTUAL | 2023-09-15 | 2023-10-10 | ACTUAL | null | null | null | 2023-09-15 | 2023-10-10 | ACTUAL | 2020-04-07 | ACTUAL | 2020-04-07 | 2023-09 | 2023-09-30 | 2021-09-01 | ACTUAL | 2021-09-01 | 2021-09-01 | ACTUAL | 2021-09-01 | null | INTERVENTIONAL | null | Safety population consisted of all enrolled participants and was to be used for all efficacy and safety analyses. | A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study | A Double-blind, Multicenter, Long-term Follow-up Study to Assess Recurrence of Actinic Keratosis in Subjects Treated With Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) or Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT), for Subjects Achieving Complete Response of Treated Lesions at Final Visit in Study RD.06.SPR.112199 | TERMINATED | null | PHASE3 | 125 | ACTUAL | Galderma R&D | This LTFU study was terminated early by the Sponsor because in the main study RD.06.SPR.112199, the primary analysis did not show superiority of MAL 16.8% cream with DL-PDT over vehicle cream with DL-PDT in terms of participant complete response (CR), and the sponsor decided not to apply for marketing authorization for the MAL 16.8% cream in combination with DL-PDT. | 2 | null | The study was terminated early as per Sponsor's decision | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 05:34:40.88875 | 2024-10-16 05:34:40.88875 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT05730673 | null | 2023-02-07 | null | null | 2023-02-15 | 2023-02-07 | 2023-02-16 | ACTUAL | null | null | null | null | null | null | 2023-02-15 | 2023-02-17 | ACTUAL | 2022-09-20 | ESTIMATED | 2022-09-20 | 2023-02 | 2023-02-28 | 2023-08-10 | ESTIMATED | 2023-08-10 | 2023-05-27 | ESTIMATED | 2023-05-27 | null | INTERVENTIONAL | null | null | Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer | A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC) | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | CytoDyn, Inc. | null | 1 | null | No participants enrolled | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT04964388 | null | 2021-07-07 | 2024-05-17 | null | 2024-06-26 | 2021-07-07 | 2021-07-16 | ACTUAL | 2024-06-26 | 2024-07-24 | ACTUAL | null | null | null | 2024-06-26 | 2024-07-24 | ACTUAL | 2021-11-09 | ACTUAL | 2021-11-09 | 2024-06 | 2024-06-30 | 2023-07-01 | ACTUAL | 2023-07-01 | 2023-05-01 | ACTUAL | 2023-05-01 | null | INTERVENTIONAL | null | null | Effect of GLP-1 Receptor Agonists on Trabecular Bone Score | Effect of GLP-1 Receptor Agonists on Trabecular Bone Score and Visceral Adiposity in Postmenopausal Women With Type 2 Diabetes Mellitus. | TERMINATED | null | PHASE2 | 5 | ACTUAL | University of Mississippi Medical Center | null | 2 | null | Not able to recruit participants | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | No sharing | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03969420 | null | 2019-05-29 | 2022-06-09 | null | 2023-11-07 | 2019-05-29 | 2019-05-31 | ACTUAL | 2022-09-22 | 2022-10-19 | ACTUAL | null | null | null | 2023-11-07 | 2023-11-09 | ACTUAL | 2020-01-15 | ACTUAL | 2020-01-15 | 2023-11 | 2023-11-30 | 2021-05-14 | ACTUAL | 2021-05-14 | 2021-04-22 | ACTUAL | 2021-04-22 | null | INTERVENTIONAL | null | null | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy | TERMINATED | null | PHASE2 | 11 | ACTUAL | Sumitomo Pharma America, Inc. | null | 4 | null | Business decision to terminate the development of alvocidib program on 17 November 2020. Patients permitted on treatment until April 22, 2021. The last end-of-treatment follow-up completed on May 14, 2021. | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT03123588 | null | 2017-04-17 | 2021-08-02 | null | 2021-10-21 | 2017-04-19 | 2017-04-21 | ACTUAL | 2021-10-21 | 2021-11-19 | ACTUAL | null | null | null | 2021-10-21 | 2021-11-19 | ACTUAL | 2017-11-14 | ACTUAL | 2017-11-14 | 2021-10 | 2021-10-31 | 2020-08-03 | ACTUAL | 2020-08-03 | 2020-08-03 | ACTUAL | 2020-08-03 | null | INTERVENTIONAL | null | null | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | TERMINATED | null | PHASE2 | 12 | ACTUAL | Incyte Corporation | null | 2 | null | Enrollment issues | t | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | NCT03147742 | APPROVED_FOR_MARKETING | null | null | null | 2,020 | 0 |
NCT03235180 | null | 2017-07-27 | 2021-10-15 | null | 2021-10-15 | 2017-07-31 | 2017-08-01 | ACTUAL | 2021-10-15 | 2021-11-10 | ACTUAL | null | null | null | 2021-10-15 | 2021-11-10 | ACTUAL | 2017-06-16 | ACTUAL | 2017-06-16 | 2021-10 | 2021-10-31 | 2021-10-12 | ACTUAL | 2021-10-12 | 2021-10-12 | ACTUAL | 2021-10-12 | null | INTERVENTIONAL | null | null | Ultrasound Evaluation of Crohn's Disease | Ultrasound Evaluation of Crohn's Disease | TERMINATED | null | PHASE4 | 9 | ACTUAL | Mayo Clinic | null | 1 | null | Unable to secure funding. | f | null | null | null | f | f | t | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04740970 | null | 2021-02-03 | null | null | 2021-04-29 | 2021-02-03 | 2021-02-05 | ACTUAL | null | null | null | null | null | null | 2021-04-29 | 2021-05-04 | ACTUAL | 2021-03-24 | ESTIMATED | 2021-03-24 | 2021-04 | 2021-04-30 | 2022-07-20 | ESTIMATED | 2022-07-20 | 2022-06-02 | ESTIMATED | 2022-06-02 | null | INTERVENTIONAL | null | null | A Study of JNJ-64304500 in Participants With Alopecia Areata | A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-64304500 in Patients With Alopecia Areata | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Janssen Research & Development, LLC | null | 2 | null | Sponsor Decision. | f | null | null | null | t | t | f | null | null | t | null | null | null | null | https://www.janssen.com/clinical-trials/transparency | YES | The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04137887 | null | 2019-10-11 | 2023-03-30 | null | 2023-05-11 | 2019-10-22 | 2019-10-24 | ACTUAL | 2023-05-11 | 2023-06-08 | ACTUAL | null | null | null | 2023-05-11 | 2023-06-08 | ACTUAL | 2019-11-04 | ACTUAL | 2019-11-04 | 2023-05 | 2023-05-31 | 2020-05-31 | ACTUAL | 2020-05-31 | 2020-05-31 | ACTUAL | 2020-05-31 | null | INTERVENTIONAL | null | Analysis was performed on all vaccinated participants. | Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older | Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine Versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older | TERMINATED | null | PHASE3 | 33,096 | ACTUAL | Sanofi | COVID-19 severely impacted the study resulting in low influenza circulation and disruption of trial recruitment for subsequent seasons (no enrollment done for seasons 2020-21 \& 2021-22). Moreover, the events collected as primary outcomes could have been driven by COVID cases, diluting the effect of influenza vaccines on such events. The study was prematurely terminated. | 2 | null | Enrollment terminated due to the COVID-19 pandemic | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | YES | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04403282 | null | 2020-05-21 | null | null | 2024-01-29 | 2020-05-26 | 2020-05-27 | ACTUAL | null | null | null | null | null | null | 2024-01-29 | 2024-01-31 | ACTUAL | 2020-09-27 | ACTUAL | 2020-09-27 | 2024-01 | 2024-01-31 | 2023-06-22 | ACTUAL | 2023-06-22 | 2023-06-22 | ACTUAL | 2023-06-22 | null | INTERVENTIONAL | null | null | Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial | Topical Eflornithine Hydrochloride for Pseudofolliculitis Barbae: A Randomized, Double-blinded, Placebo-controlled Trial | TERMINATED | null | PHASE4 | 9 | ACTUAL | Walter Reed National Military Medical Center | null | 2 | null | Vaniqa no longer manufactured | f | null | null | null | f | t | f | null | null | t | null | null | null | null | null | NO | The PI will compile the names of the patients who are followed through week 16 in order to create the master subject list. Using the information stored on the master subject list (name, social security number, Medical Record Number), the research team will obtain data electronically from the patient medical records. Specifically, the lesion and hair counts on the face will be acquired. This will be recorded on the master data sheet. The master subject list will be password protected and only accessible to study personnel within the Walter Reed National Military Medical Center (WRNMMC) network. The master data sheet will be coded and available to the investigators and may be shared with research assistants or statisticians. | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | FED | null | null | null | null | null | null | 2,023 | 0 |
NCT03988647 | null | 2019-06-13 | 2021-07-07 | null | 2021-08-05 | 2019-06-13 | 2019-06-17 | ACTUAL | 2021-08-05 | 2021-08-09 | ACTUAL | null | null | null | 2021-08-05 | 2021-08-09 | ACTUAL | 2019-07-24 | ACTUAL | 2019-07-24 | 2021-08 | 2021-08-31 | 2021-01-20 | ACTUAL | 2021-01-20 | 2020-11-16 | ACTUAL | 2020-11-16 | null | INTERVENTIONAL | null | null | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | A Phase 2 Study of Palliative Radiation Therapy and Anti-PD-1/PD-L1 Checkpoint Blockade in Patients With Metastatic Merkel Cell Carcinoma | TERMINATED | null | PHASE2 | 1 | ACTUAL | Stanford University | null | 1 | null | Business decision | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT02119000 | null | 2014-01-26 | null | null | 2021-02-22 | 2014-04-17 | 2014-04-21 | ESTIMATED | null | null | null | null | null | null | 2021-02-22 | 2021-02-24 | ACTUAL | 2015-08 | null | 2015-08-31 | 2021-02 | 2021-02-28 | 2020-01 | ACTUAL | 2020-01-31 | 2020-01 | ACTUAL | 2020-01-31 | null | INTERVENTIONAL | null | null | Comparison of Two Types of Bowel Preparation for Inpatient Colonoscopy | null | TERMINATED | null | PHASE4 | 82 | ACTUAL | McGill University Health Centre/Research Institute of the McGill University Health Centre | null | 2 | null | Difficulty in recruitment | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT05084456 | null | 2019-03-25 | null | null | 2021-10-18 | 2021-10-18 | 2021-10-19 | ACTUAL | null | null | null | null | null | null | 2021-10-18 | 2021-10-19 | ACTUAL | 2017-07 | ESTIMATED | 2017-07-31 | 2021-10 | 2021-10-31 | 2020-04 | ESTIMATED | 2020-04-30 | 2020-02 | ESTIMATED | 2020-02-29 | null | INTERVENTIONAL | null | null | Oral Docetaxel in Patients With Normal or Impaired Liver Function | Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir in Patients With Normal or Impaired Liver Function | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Modra Pharmaceuticals | null | 3 | null | Pending further development | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:55:33.932217 | 2024-10-17 02:55:33.932217 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT03417401 | null | 2017-11-20 | null | null | 2023-03-22 | 2018-01-24 | 2018-01-31 | ACTUAL | null | null | null | null | null | null | 2023-03-22 | 2023-03-23 | ACTUAL | 2018-10-16 | ESTIMATED | 2018-10-16 | 2023-03 | 2023-03-31 | 2021-12-10 | ACTUAL | 2021-12-10 | 2021-12-10 | ACTUAL | 2021-12-10 | null | INTERVENTIONAL | null | null | Surgical Stabilizer Assisted RVC With rtPA for CRVO | Phase Ib Study on Surgical Stabilizer Assisted Retinal Vein Cannulation (RVC) With tPA Infusion Confirmed by Intraoperative Angio-optical Coherence Tomography (Angio-OCT) for the Treatment of Central Retinal Vein Occlusion (CRVO). | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Universitaire Ziekenhuizen KU Leuven | null | 1 | null | organizationally not yet possible | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03854032 | null | 2019-02-21 | null | null | 2024-07-25 | 2019-02-21 | 2019-02-26 | ACTUAL | null | null | null | null | null | null | 2024-07-25 | 2024-07-29 | ACTUAL | 2019-04-09 | ACTUAL | 2019-04-09 | 2024-07 | 2024-07-31 | 2024-06-12 | ACTUAL | 2024-06-12 | 2024-06-12 | ACTUAL | 2024-06-12 | null | INTERVENTIONAL | null | null | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | Window-of-Opportunity Trial of Nivolumab and BMS986205 in Patients With Squamous Cell Carcinoma of the Head and Neck (CA017-087) | TERMINATED | null | PHASE2 | 45 | ACTUAL | Thomas Jefferson University | null | 2 | null | toxicity - per sponsor | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT03780725 | null | 2018-11-26 | null | null | 2021-11-03 | 2018-12-18 | 2018-12-19 | ACTUAL | null | null | null | null | null | null | 2021-11-03 | 2021-11-05 | ACTUAL | 2019-01-22 | ACTUAL | 2019-01-22 | 2021-11 | 2021-11-30 | 2020-12-08 | ACTUAL | 2020-12-08 | 2020-02-19 | ACTUAL | 2020-02-19 | null | INTERVENTIONAL | null | null | This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 | An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 754111 in Patients With Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma Treated With BI 754111 in Combination With BI 754091 | TERMINATED | null | PHASE1 | 8 | ACTUAL | Boehringer Ingelheim | null | 2 | null | Due to company decision. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:~1. studies in products where Boehringer Ingelheim is not the license holder;~2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;~3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datasharing | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04328285 | null | 2020-03-25 | null | null | 2023-02-28 | 2020-03-27 | 2020-03-31 | ACTUAL | null | null | null | null | null | null | 2023-02-28 | 2023-03-01 | ACTUAL | 2020-04-14 | ACTUAL | 2020-04-14 | 2023-02 | 2023-02-28 | 2022-03-30 | ACTUAL | 2022-03-30 | 2020-05-13 | ACTUAL | 2020-05-13 | null | INTERVENTIONAL | COVIDAXIS | null | Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers | Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial | TERMINATED | null | PHASE3 | 118 | ACTUAL | Centre Hospitalier Universitaire de Saint Etienne | null | 2 | null | French authority's decision | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04488185 | null | 2020-06-26 | null | null | 2023-03-28 | 2020-07-23 | 2020-07-27 | ACTUAL | null | null | null | null | null | null | 2023-03-28 | 2023-03-31 | ACTUAL | 2020-11-02 | ACTUAL | 2020-11-02 | 2023-03 | 2023-03-31 | 2021-03-24 | ACTUAL | 2021-03-24 | 2021-03-24 | ACTUAL | 2021-03-24 | null | INTERVENTIONAL | INTERCEPT | null | An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound | An Exploratory, Randomized, Double-blind, Parallel-group, Multicenter Study to Compare Secukinumab 300 mg With Placebo After 16 Weeks of Treatment in Adults With Moderate to Severe Plaque Psoriasis and Subclinical Enthesitis Measured by Musculoskeletal Ultrasound | WITHDRAWN | null | PHASE4 | 0 | ACTUAL | Novartis | null | 2 | null | low recruitment | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | YES | Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT03345004 | null | 2017-11-01 | 2021-11-23 | null | 2022-04-11 | 2017-11-13 | 2017-11-17 | ACTUAL | 2022-04-11 | 2023-01-09 | ACTUAL | null | null | null | 2022-04-11 | 2023-01-09 | ACTUAL | 2017-12-20 | ACTUAL | 2017-12-20 | 2022-04 | 2022-04-30 | 2021-04-27 | ACTUAL | 2021-04-27 | 2020-07-13 | ACTUAL | 2020-07-13 | null | INTERVENTIONAL | null | null | Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes | A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes | COMPLETED | null | PHASE2 | 109 | ACTUAL | Diamyd Medical AB | null | 2 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT00061282 | null | 2003-05-23 | null | null | 2022-12-07 | 2003-05-23 | 2003-05-26 | ESTIMATED | null | null | null | null | null | null | 2022-12-07 | 2022-12-09 | ACTUAL | 2002-09-30 | ACTUAL | 2002-09-30 | 2022-12 | 2022-12-31 | 2020-12-01 | ACTUAL | 2020-12-01 | 2020-12-01 | ACTUAL | 2020-12-01 | null | INTERVENTIONAL | CAPTURE | null | Clotrimazole Enemas for Pouchitis in Children and Adults | Clotrimazole Enemas for Pouchitis in Children and Adults | TERMINATED | null | PHASE1/PHASE2 | 11 | ACTUAL | Boston Children's Hospital | null | 3 | null | Funding Horizon | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04946318 | null | 2021-06-23 | null | null | 2022-10-07 | 2021-06-23 | 2021-06-30 | ACTUAL | null | null | null | null | null | null | 2022-10-07 | 2022-10-10 | ACTUAL | 2021-09-08 | ACTUAL | 2021-09-08 | 2022-10 | 2022-10-31 | 2022-09-08 | ACTUAL | 2022-09-08 | 2022-09-08 | ACTUAL | 2022-09-08 | null | INTERVENTIONAL | null | null | Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma | A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age | TERMINATED | null | PHASE2 | 136 | ACTUAL | Novartis | null | 6 | null | Sponsor Decision | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com | 2024-10-16 06:15:19.053453 | 2024-10-16 06:15:19.053453 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04915950 | null | 2021-06-01 | 2023-08-30 | null | 2023-12-01 | 2021-06-01 | 2021-06-07 | ACTUAL | 2023-12-01 | 2023-12-22 | ACTUAL | null | null | null | 2023-12-01 | 2023-12-22 | ACTUAL | 2021-11-03 | ACTUAL | 2021-11-03 | 2023-12 | 2023-12-31 | 2022-09-02 | ACTUAL | 2022-09-02 | 2022-09-02 | ACTUAL | 2022-09-02 | null | INTERVENTIONAL | null | The full analysis set (FAS) included all randomized participants, irrespective of whether they received any study treatment. | A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis | TERMINATED | null | PHASE2 | 13 | ACTUAL | Pfizer | This study was terminated early due to a business decision that was not due to any safety concerns. The number of participants was smaller than originally planned and only summary statistics were therefore generated for primary and secondary outcome measures. | 6 | null | Business decision | f | null | null | null | f | t | f | null | null | null | null | null | null | null | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests | YES | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04872101 | null | 2021-04-29 | null | null | 2023-01-06 | 2021-04-29 | 2021-05-04 | ACTUAL | null | null | null | null | null | null | 2023-01-06 | 2023-01-09 | ACTUAL | 2021-05-25 | ACTUAL | 2021-05-25 | 2023-01 | 2023-01-31 | 2023-01-06 | ACTUAL | 2023-01-06 | 2022-12-27 | ACTUAL | 2022-12-27 | null | INTERVENTIONAL | DELTA 2 | null | Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) | A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2) | COMPLETED | null | PHASE3 | 473 | ACTUAL | LEO Pharma | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | Data is available to request after results of the trial are available on leopharmatrials.com | Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement. | http://leopharmatrials.com/for-professionals | YES | De-identified IPD can be made available to researchers in a closed environment for a specified period of time. | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT03418480 | null | 2017-11-15 | null | null | 2024-02-06 | 2018-01-31 | 2018-02-01 | ACTUAL | null | null | null | null | null | null | 2024-02-06 | 2024-02-07 | ACTUAL | 2017-04-11 | ACTUAL | 2017-04-11 | 2024-02 | 2024-02-29 | 2024-01-24 | ACTUAL | 2024-01-24 | 2023-11-01 | ACTUAL | 2023-11-01 | null | INTERVENTIONAL | HARE-40 | null | HARE-40: HPV Anti-CD40 RNA vaccinE | Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma | COMPLETED | null | PHASE1/PHASE2 | 32 | ACTUAL | University of Southampton | null | 2 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT04776876 | null | 2021-02-08 | null | null | 2021-09-23 | 2021-02-25 | 2021-03-02 | ACTUAL | null | null | null | null | null | null | 2021-09-23 | 2021-09-29 | ACTUAL | 2021-03-01 | ESTIMATED | 2021-03-01 | 2021-09 | 2021-09-30 | 2021-09-02 | ACTUAL | 2021-09-02 | 2021-09-02 | ACTUAL | 2021-09-02 | null | INTERVENTIONAL | null | null | Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome | A Phase II, Open-Label, Single-Arm Study of INCMGA00012 and Telotristat Ethyl in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | M.D. Anderson Cancer Center | null | 1 | null | The study will not be opening. Support was withdrawn. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04748588 | null | 2021-02-08 | null | null | 2023-04-14 | 2021-02-08 | 2021-02-10 | ACTUAL | null | null | null | null | null | null | 2023-04-14 | 2023-04-19 | ACTUAL | 2021-02-12 | ACTUAL | 2021-02-12 | 2021-01 | 2021-01-31 | 2022-01-31 | ACTUAL | 2022-01-31 | 2022-01-31 | ACTUAL | 2022-01-31 | null | INTERVENTIONAL | CATCO-NOS | null | Treatment of Nosocomial COVID-19 | Canadian Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Nosocomial Acquired COVID-19 Patients | TERMINATED | null | PHASE4 | 46 | ACTUAL | University of Calgary | null | 2 | null | Equipoise requirement no longer met. | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT03362593 | null | 2017-11-22 | null | null | 2020-08-27 | 2017-12-04 | 2017-12-05 | ACTUAL | null | null | null | null | null | null | 2020-08-27 | 2020-08-31 | ACTUAL | 2017-12-04 | ACTUAL | 2017-12-04 | 2020-08 | 2020-08-31 | 2020-05-11 | ACTUAL | 2020-05-11 | 2020-05-11 | ACTUAL | 2020-05-11 | null | INTERVENTIONAL | null | null | A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses | A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Oral Formulation and Determination of Intravenous Pharmacokinetics | TERMINATED | null | PHASE1 | 186 | ACTUAL | MedImmune LLC | null | 3 | null | The program is canceled due to company strategic reasons. | f | null | null | null | f | f | f | null | null | null | null | null | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. | When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. | https://astrazenecagroup-dt.pharmacm.com/DT/Home | YES | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ standards. | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT03562507 | null | 2018-06-08 | 2023-10-05 | null | 2024-05-17 | 2018-06-08 | 2018-06-19 | ACTUAL | 2024-05-17 | 2024-05-20 | ACTUAL | null | null | null | 2024-05-17 | 2024-05-20 | ACTUAL | 2019-04-11 | ACTUAL | 2019-04-11 | 2024-05 | 2024-05-31 | 2022-10-18 | ACTUAL | 2022-10-18 | 2022-10-18 | ACTUAL | 2022-10-18 | null | INTERVENTIONAL | ERICA | No patients were enrolled in the ESK984 and Nivolumab combo arm | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma | ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma | TERMINATED | null | PHASE2 | 8 | ACTUAL | University of Michigan Rogel Cancer Center | null | 2 | null | Lack of patient population | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT03580187 | null | 2018-06-14 | null | null | 2022-09-21 | 2018-07-02 | 2018-07-09 | ACTUAL | null | null | null | null | null | null | 2022-09-21 | 2022-09-23 | ACTUAL | 2018-06-14 | ACTUAL | 2018-06-14 | 2022-09 | 2022-09-30 | 2020-04-15 | ACTUAL | 2020-04-15 | 2020-04-15 | ACTUAL | 2020-04-15 | null | INTERVENTIONAL | null | null | Nebulized Morphine in Chest Trauma Patients: A Prospective Study | Nebulized Morphine in Chest Trauma Patients: A Prospective Study | COMPLETED | null | PHASE3 | 75 | ACTUAL | University Hospital, Mahdia | null | 1 | null | null | f | null | null | null | f | f | f | null | null | f | null | null | null | null | null | UNDECIDED | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT02582996 | null | 2015-03-31 | null | null | 2019-04-09 | 2015-10-20 | 2015-10-21 | ESTIMATED | null | null | null | null | null | null | 2019-04-09 | 2019-04-10 | ACTUAL | 2020-04 | ESTIMATED | 2020-04-30 | 2019-04 | 2019-04-30 | 2021-06 | ESTIMATED | 2021-06-30 | 2021-04 | ESTIMATED | 2021-04-30 | null | INTERVENTIONAL | null | null | Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks | National, Phase III, Multicenter, Randomized, Open, Parallel, to Evaluate the Efficacy, Safety and Superiority of Cefalium® Compared to the Tylenol® in the Treatment of Migraine Attacks | SUSPENDED | null | PHASE3 | 336 | ESTIMATED | Ache Laboratorios Farmaceuticos S.A. | null | 2 | null | Strategic reasons of the company | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 05:34:40.88875 | 2024-10-16 05:34:40.88875 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT03554109 | null | 2018-05-25 | null | null | 2022-03-28 | 2018-06-11 | 2018-06-12 | ACTUAL | null | null | null | null | null | null | 2022-03-28 | 2022-04-05 | ACTUAL | 2018-09 | ESTIMATED | 2018-09-30 | 2018-08 | 2018-08-31 | 2021-12 | ESTIMATED | 2021-12-31 | 2020-06 | ESTIMATED | 2020-06-30 | null | INTERVENTIONAL | TNBC | null | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | ImmunityBio, Inc. | null | 2 | null | Trial not initiated | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT02077621 | null | 2014-02-24 | null | null | 2023-11-23 | 2014-03-02 | 2014-03-04 | ESTIMATED | null | null | null | null | null | null | 2023-11-23 | 2023-11-27 | ACTUAL | 2014-02 | ESTIMATED | 2014-02-28 | 2023-11 | 2023-11-30 | 2020-12 | ACTUAL | 2020-12-31 | 2020-12 | ESTIMATED | 2020-12-31 | null | INTERVENTIONAL | null | null | Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer | The Phase II Clinical Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | PhytoHealth Corporation | null | 2 | null | Study reevaluation | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04565327 | null | 2020-09-21 | 2023-10-18 | null | 2023-10-18 | 2020-09-21 | 2020-09-25 | ACTUAL | 2023-10-18 | 2023-11-13 | ACTUAL | null | null | null | 2023-10-18 | 2023-11-13 | ACTUAL | 2020-08-14 | ACTUAL | 2020-08-14 | 2023-10 | 2023-10-31 | 2022-11-01 | ACTUAL | 2022-11-01 | 2022-11-01 | ACTUAL | 2022-11-01 | null | INTERVENTIONAL | null | No participants were assigned to Cohort A | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | TERMINATED | null | PHASE2 | 7 | ACTUAL | University of California, San Francisco | Study closed earlier than expected due to slow accrual | 2 | null | Slow accrual | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04604132 | null | 2020-10-21 | 2023-11-21 | null | 2024-03-06 | 2020-10-21 | 2020-10-27 | ACTUAL | 2024-03-06 | 2024-04-04 | ACTUAL | null | null | null | 2024-03-06 | 2024-04-04 | ACTUAL | 2020-10-06 | ACTUAL | 2020-10-06 | 2024-03 | 2024-03-31 | 2022-11-21 | ACTUAL | 2022-11-21 | 2022-11-21 | ACTUAL | 2022-11-21 | null | INTERVENTIONAL | FIDES-03 | null | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma | A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations | TERMINATED | null | PHASE1/PHASE2 | 47 | ACTUAL | Basilea Pharmaceutica | null | 5 | null | Terminated prematurely for administrative reasons not related to patient safety. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04691232 | null | 2020-12-07 | null | null | 2023-10-16 | 2020-12-28 | 2020-12-31 | ACTUAL | null | null | null | null | null | null | 2023-10-16 | 2023-10-17 | ACTUAL | 2021-02-22 | ACTUAL | 2021-02-22 | 2022-01 | 2022-01-31 | 2023-05-22 | ACTUAL | 2023-05-22 | 2023-04-12 | ACTUAL | 2023-04-12 | null | INTERVENTIONAL | null | null | Autologous Ex Vivo Expanded Regulatory T Cells in Ulcerative Colitis | Phase I, Open-label, Fast-track Dose-escalation Clinical Trial Exploring the Safety and the Tolerability of Autologous ex Vivo Expanded Regulatory T Cells in Adults With Ulcerative Colitis | COMPLETED | null | PHASE1 | 11 | ACTUAL | University of Erlangen-Nürnberg Medical School | null | 1 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT04444830 | null | 2020-06-07 | null | null | 2022-07-27 | 2020-06-22 | 2020-06-24 | ACTUAL | null | null | null | null | null | null | 2022-07-27 | 2022-07-29 | ACTUAL | 2021-01 | ESTIMATED | 2021-01-31 | 2022-03 | 2022-03-31 | 2021-09-21 | ACTUAL | 2021-09-21 | 2021-09-21 | ACTUAL | 2021-09-21 | null | INTERVENTIONAL | null | null | Sprix for Postoperative Pain Control Following Gynecologic Surgery | Can Intranasal Ketorolac Tromethamine Prescribed Postoperatively After Major Female Pelvic Reconstructive Surgery Reduce Consumption of Prescribed Narcotics? | WITHDRAWN | null | PHASE4 | 0 | ACTUAL | University of Louisville | null | 2 | null | Study never opened to enrollment. Study never IRB approved. | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04167462 | null | 2019-11-15 | 2022-10-06 | 2022-03-07 | 2023-02-08 | 2019-11-15 | 2019-11-18 | ACTUAL | 2022-10-06 | 2022-11-02 | ACTUAL | 2022-03-07 | 2022-03-08 | ACTUAL | 2023-02-08 | 2023-03-08 | ACTUAL | 2019-11-25 | ACTUAL | 2019-11-25 | 2023-02 | 2023-02-28 | 2022-01-07 | ACTUAL | 2022-01-07 | 2021-03-08 | ACTUAL | 2021-03-08 | null | INTERVENTIONAL | POETYK-PSO-3 | null | An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis | COMPLETED | null | PHASE3 | 220 | ACTUAL | Bristol-Myers Squibb | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
Subsets and Splits